英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
090976查看　090976　在百度字典中的解释百度英翻中〔查看〕
090976查看　090976　在Google字典中的解释Google英翻中〔查看〕
090976查看　090976　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Advancing hypoparathyroidism treatment: FDA approval of . . .
    This approval marks a critical milestone in endocrine therapeutics and offers renewed hope for patients struggling with the burdens of chronic HypoPT Keywords: calcium homeostasis, FDA approval, hypoparathyroidism, orphan drug, Palopegteriparatide, parathyroid hormone, Yorvipath
  • Revised European Society of Endocrinology Clinical Practice . . .
    Abstract In the present European Society of Endocrinology (ESE) clinical guideline, we present recommendations for the diagnosis, management, and monitoring of chronic hypoparathyroidism (HypoPT) in adults Management of HypoPT has changed since the first ESE clinical guideline was published in 2015, as has the knowledge on patient burden of the disease, and the understanding of associated
  • Palopegteriparatide - Wikipedia
    Palopegteriparatide, sold under the brand name Yorvipath, is a hormone replacement therapy used for the treatment of hypoparathyroidism [2][3] It is a transiently pegylated parathyroid hormone [5] It is a parathyroid hormone analog [2] Palopegteriparatide was approved for medical use in the European Union in November 2023, [3] and in the United States in August 2024 [2][6][7][8]
  • YORVIPATH: First Hypoparathyroidism Treatment in Adults
    YORVIPATH is a prodrug of parathyroid hormone (PTH 1-34) administered once daily, designed to provide parathyroid hormone levels within the normal physiological range across the 24-hour dosing period YORVIPATH was granted marketing authorization by the European Commission (EC) in November 2023 as a PTH replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism
  • Palopegteriparatide (YORVIPATH) in Hypoparathyroidism
    Palopegteriparatide (YORVIPATH) in Hypoparathyroidism National Drug Mini-monograph June 2025 VA Pharmacy Benefits Management Services and National Formulary Committee The purpose of VA National Formulary Committee drug monographs is to provide a focused drug review for making formulary decisions
  • Take Charge of Hypopara | YORVIPATH® (palopegteriparatide)
    Official Patient site for YORVIPATH for chronic hypoparathyroidism in adults See full Prescribing Information Important Safety Information
  • Early U. S. Real-World Treatment Patterns and Outcomes in . . .
    To examine the impact of palopegteriparatide (YORVIPATH; TransCon PTH) on real-world clinical outcomes in adult patients with hypoparathyroidism
  • Yorvipath, INN-palopegteriparatide - European Medicines Agency
    Treatment should be started and monitored by a doctor or a qualified healthcare professional experienced in the diagnosis and management of patients with chronic hypoparathyroidism For more information about using Yorvipath, see the package leaflet or contact your doctor or pharmacist How does Yorvipath work?
  • Chronic Hypoparathyroidism—Current and Emerging Therapies
    Conventional treatment for hypoparathyroidism with calcium salts and activated vitamin D has limitations such as inadequate control of symptomatic hypocalcemia and large pill burden PTH replacement therapy offers a more physiologic alternative to conventional therapy





中文字典-英文字典  2005-2009